32IN - Conclusions and perspectives
|Date||01 October 2012|
|Event||ESMO Congress 2012|
|Session||A paradigm shift in early drug development: Individualizing to more patient benefit|
|Topics|| Drug Development
Early clinical drug development in cancer included mainly the phase I program (aims: DLTs and recommended doses) and early phase II studies (aim: antitumor activity). In the era of molecular biology and the development of targeted agents, the frontier between these phases became less visible. Individualizing the early drug development process (from study design to patient/tumor selection) has lead to more patient benefit as recently illustrated in several commom and orphan solid tumors. This paradigm shift will be intensified in the near future by better patient selection, molecular target discovery, anticancer drugs selectivity, deeper understanding of the biology of the tumors and mechanisms of sensitivity/resistance and the emerging role of molecular imaging to “map” the tumor and to document as early as possible the tumor progression to the costly new anticancer agents. All these issues will be developed by colleagues in this special symposium. My task will be to conclude and to present some perspectives. These will be based among others on the development of new technologies, the understanding of the behaviour of primiray tumors and metastases and the integration of biological and technological advances into early clinical research investigation of new targeted agents.Disclosure
The author has declared no conflicts of interest.